PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
20.45%
R&D growth above 1.5x AGEN's 1.96%. Michael Burry would check for spending discipline.
69.30%
G&A growth above 1.5x AGEN's 0.94%. Michael Burry would check for operational inefficiency.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
30.79%
Operating expenses growth above 1.5x AGEN's 0.94%. Michael Burry would check for inefficiency.
30.79%
Total costs growth above 1.5x AGEN's 1.76%. Michael Burry would check for inefficiency.
No Data
No Data available this quarter, please select a different quarter.
1.90%
D&A growth while AGEN reduces D&A. John Neff would investigate differences.
-31.40%
EBITDA decline while AGEN shows 15.96% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-30.79%
Operating income decline while AGEN shows 12.69% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-10.20%
Other expenses reduction while AGEN shows 3.42% growth. Joel Greenblatt would examine advantage.
-31.28%
Pre-tax income decline while AGEN shows 10.78% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-264.58%
Tax expense reduction while AGEN shows 32.97% growth. Joel Greenblatt would examine advantage.
-31.28%
Net income decline while AGEN shows 10.19% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-21.00%
EPS decline while AGEN shows 12.10% growth. Joel Greenblatt would examine position.
-22.22%
Diluted EPS decline while AGEN shows 12.10% growth. Joel Greenblatt would examine position.
7.78%
Share count reduction below 50% of AGEN's 2.22%. Michael Burry would check for concerns.
7.68%
Diluted share reduction below 50% of AGEN's 2.22%. Michael Burry would check for concerns.